Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Actavis execs up for $101M in merger-related bonuses, if investors approve

Through a storm of M&A activity, Actavis CEO Brent Saunders has climbed his way up into the CEO's chair at one of pharma's top 10 drugmakers--and it's a climb for which he's been well rewarded.

Whistleblowers say Teva used kickbacks to push up Copaxone, Azilect sales

Teva Pharmaceutical Industries is facing U.S. allegations that it used kickbacks, disguised as speaking fees, to persuade doctors to boost prescriptions of its multiple sclerosis drug Copaxone and Parkinson's med Azilect.

Celltrion revs up Remicade biosim for U.S. rollout this year

Watch out, Remicade. South Korea-based Celltrion is gunning to launch its biosimilar version, Remsima, in the U.S. by the end of this year.

Indian pharma exec: Compulsory licensing cost us $10B in investment

India-based Hetero Pharma's director adopted a heretical position in the local pharmaceutical industry when he said use of the compulsory licensing process has cost India $10 billion in potential investments.

Heavyweight PBMs mean trouble for Big Pharma's pricey new meds

The good news for drugmakers, after UnitedHealth agreed to buy Catamaran: You might need fewer staffers to negotiate with pharmacy benefits managers, now that 1 billion U.S. scripts a year will be controlled by three players.

Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers

Bristol-Myers Squibb and Otsuka won't have to fight claims that they promoted Abilify for off-label uses or used kickbacks to persuade doctors to prescribe the antipsychotic drug. A U.S. judge tossed out those allegations, leveled by a couple of whistleblowers in 2011, for lack of specific evidence.

Gilead's huge Sovaldi payoff yields a nice 23% pay hike for CEO

For several years, Gilead Sciences CEO John Martin has collected annual compensation worth about $15 million and his stock gains since 2009 run into the hundreds of millions. But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff in 2015.

Sanofi would be just fine without more M&A, chairman says

Sanofi Chairman Serge Weinberg says his company can do without dealmaking. And good thing, Weinberg told Les Echos--because the potential buys on the market are too expensive.

Pfizer's Lyrica patent fight in England puts NHS docs, pharmacists on defensive

Talk about unintended consequences of a patent ruling. Pfizer's unprecedented effort to fight Lyrica copies in England has doctors and pharmacists squabbling, and the National Health Service stepping in to keep the peace.

Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015

Suffering from generic competition and patent losses, Eli Lilly & Co. froze salaries and cut bonuses last year--from the top management ranks on down. But the decreases in incentive pay didn't make a huge dent in those executive pay packages.